Plasmodium falciparum Malaria: Reduction of Endothelial Cell Apoptosis In Vitro

Christoph Josef Hemmer,1* Hans Anton Lehr,2 Kathi Westphal,1 Marcus Unverricht,1 Manja Kratzius,1 and Emil Christian Reisinger1

Division of Tropical Medicine and Infectious Diseases, Department of Medicine, University of Rostock Medical School, Rostock,1 and Department of Pathology, University of Mainz Medical School, Mainz,2 Germany

Received 7 June 2004/Returned for modification 13 July 2004/Accepted 1 October 2004

Organ failure in Plasmodium falciparum malaria is associated with neutrophil activation and endothelial damage. This study investigates whether neutrophil-induced endothelial damage involves apoptosis and whether it can be prevented by neutralization of neutrophil secretory products. Endothelial cells from human umbilical veins were coincubated with neutrophils from healthy donors and with sera from eight patients with P. falciparum malaria, three patients with P. vivax malaria, and three healthy controls. Endothelial apoptosis was demonstrated by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) and annexin V staining. The rate of apoptosis of cells was markedly increased after incubation with patient serum compared to that with control serum. Apoptosis was most pronounced after incubation with sera from two patients with fatal cases of P. falciparum malaria, followed by sera of survivors with severe P. falciparum malaria and, finally, by sera of patients with mild P. falciparum and P. vivax malaria. Ascorbic acid, tocopherol, and ulinastatin reduced the apoptosis rate, but gabexate mesilate and pentoxifylline did not. Furthermore, in fatal P. falciparum malaria, apoptotic endothelial cells were identified in renal and pulmonary tissue by TUNEL staining. These findings show that apoptosis caused by neutrophil secretory products plays a major role in endothelial cell damage in malaria. The antioxidants ascorbic acid and tocopherol and the protease inhibitor ulinastatin can reduce malaria-associated endothelial apoptosis in vitro.

In P. falciparum malaria, apoptosis as a possible mechanism of endothelial cell death is suggested by elevated levels in plasma of Fas ligand (31), which triggers apoptosis by binding to Fas, its receptor on the target cell. In addition, Dürck's granulomas (aggregates of astrocytes and glial cells), seen in cerebral malaria, contain large amounts of endostatin, a collagen XVIII fragment known to induce endothelial cell apoptosis (11).

Apostosis of endothelial cells can also be caused by P. falciparum-parasitized erythrocytes in vitro (39). However, vascular leakage in P. falciparum malaria often develops several days after the initiation of antiparasitic therapy (27), even though antimalarial drugs reduce the endothelial adherence of parasitized erythrocytes (50). Therefore, interaction of parasitized erythrocytes with the vascular endothelium is probably not the only mechanism that leads to endothelial cell apoptosis in P. falciparum malaria.

This study shows that sera from patients with P. falciparum malaria—together with neutrophils—induce endothelial cell apoptosis, which can be prevented by antioxidants and inhibitors of proteolytic enzymes in vitro.

MATERIALS AND METHODS

Patients. Serum samples from two patients with fatal P. falciparum malaria, five patients with severe nonfatal P. falciparum malaria, five patients with mild P. falciparum malaria, six patients with P. vivax malaria, and six healthy controls were investigated (Table 1). All patients were nonimmune European travelers. Informed consent for taking blood samples was obtained from patients and healthy control subjects. Approval for this study was granted by the Ethics Committees of the State Medical Boards of Hamburg and Mecklenburg-Vorpommern.
**TABLE 1. Endothelial apoptosis after incubation with serum and neutrophils**

<table>
<thead>
<tr>
<th>Serum source</th>
<th>% Apoptosis (range)</th>
<th>Medan (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before therapy</td>
<td>After start of antiparasitic therapy</td>
</tr>
<tr>
<td></td>
<td>Day 7</td>
<td>Day 30</td>
</tr>
<tr>
<td>Fatal <em>P. falciparum</em> malaria (n = 2)</td>
<td>61 (54–68)</td>
<td>22 (16–28)</td>
</tr>
<tr>
<td>Severe <em>P. falciparum</em> malaria (n = 5)</td>
<td>55 (37–49)</td>
<td>24 (20–25)</td>
</tr>
<tr>
<td>Mild <em>P. falciparum</em> malaria (n = 5)</td>
<td>38 (26–42)</td>
<td>18 (15–21)</td>
</tr>
<tr>
<td><em>P. vivax</em> malaria (n = 6)</td>
<td>25 (22–40)</td>
<td>15 (9–20)</td>
</tr>
<tr>
<td>Healthy controls (n = 6)</td>
<td>15 (9–20)</td>
<td></td>
</tr>
</tbody>
</table>

*a* Median proportions of TUNEL-positive endothelial cells in relation to those of all endothelial cells.

*b* For two patients.

---

**RESULTS**

**Incubation of endothelial cells with serum.** Incubation of endothelial cells with serum from healthy controls with or without neutrophils resulted in a low number of TUNEL-positive apoptotic cells (without neutrophils, median of 10% and range of 0.5 to 14.5%; with neutrophils, median of 15% and range of 5 to 19.5%; n = 6). In contrast, incubation of endothelial cells with sera from malaria patients together with neutrophils resulted in a markedly higher number of apoptotic endothelial cells than incubation without neutrophils (Fig. 1A). In these coinoculation experiments, sera from patients with
fatal *P. falciparum* malaria showed the highest apoptosis rates (median of 61% and range of 54 to 68 for two patients), followed by sera from patients with severe *P. falciparum*, mild *P. falciparum*, and *P. vivax* malaria (Table 1). Sera from patients with fatal malaria plus neutrophils induced large defects in the endothelial cell layers, a phenomenon that is consistently seen secondary to apoptosis (58).

All sera obtained before antimalarial therapy induced a higher rate of TUNEL-positive endothelial cell nuclei than reconvalescent sera obtained 7 days later (48 versus 21% of sera from patients with severe malaria, 40 versus 21% of sera from patients with mild *P. falciparum* malaria, and 25 versus 19% of sera from patients with *P. vivax* malaria [Table 1]).

Parasitemia levels showed a significant correlation with the percentage of TUNEL-positive endothelial cell nuclei ($r = 0.751, P < 0.001$), but no correlation was seen for TNF-α concentrations in serum ($r = 0.216, P > 0.1$).

Annexin V staining confirmed the elevated rates of apoptotic endothelial cells after incubation with serum from a patient with fatal malaria and neutrophils (48% [Fig. 1B]) compared to that with control serum (10% [Fig. 1B, inset]). In fatal malaria, 28% of the annexin V-positive cells retained propidium iodide, reflecting the fact that apoptotic endothelial cells progress to necrosis more quickly than other cell types (56). The propidium iodide-retaining nuclei were round and condensed, indicating that apoptosis had been induced before the cells died. Cells negative for annexin and positive for propidium iodide were not seen, probably because dead endothelial cells detach from their matrix (23, 58).

**Transwell experiments.** In order to test whether the impact of malaria patient serum and neutrophils on endothelial apoptosis depends upon direct contact between neutrophils and endothelial cells, neutrophils were separated from endothelial cells by porous membranes during incubation. Sera from the two patients with fatal malaria led to apoptosis rates of 49 and 42%, with neutrophils in direct contact with endothelial cells; 25 and 29%, with neutrophils separated from endothelial cells by porous membranes; and 24 and 33% in the absence of neutrophils. Serum from the patient with severe nonfatal malaria led to an endothelial apoptosis rate of 43%, with neutrophils in direct contact with endothelial cells; 29%, with neutrophils separated from endothelial cells by a porous membrane; and 28% in the absence of neutrophils.

**Inhibition experiments.** The water-soluble antioxidant ascorbic acid and the urinary trypsin inhibitor ulinastatin inhibited the apoptotic effect of sera from patients with severe malaria in a concentration-dependent manner. The apoptosis rate was 68% without either substance. The apoptosis rate was reduced to 62% with $10^{-5}$ M, to 28% with $10^{-4}$ M, and to 32% with $10^{-3}$ M ascorbic acid, while $10^{-6}$ M ascorbic acid had no effect (Fig. 2c). The rank correlation between the concentrations of ascorbic acid and the apoptosis rates was 0.85 ($P =...
The apoptosis rate was reduced to 42% with $10^{-7} \text{M}$ ulinastatin and to 35% at a concentration of $10^{-5} \text{M}$, while $10^{-10} \text{M}$ ulinastatin had no effect (Fig. 2e). The rank correlation between the concentrations of ulinastatin and the apoptosis rates was 0.85 ($P < 0.001$). Likewise, the lipid-soluble antioxidant tocopherol reduced the apoptosis rate from 62 to 29% at a concentration of $10^{-3} \text{M}$, while lower concentrations had no effect (Fig. 2d).

Reduction of endothelial apoptosis by $10^{-4} \text{M}$ ascorbic acid and by $10^{-7} \text{M}$ ulinastatin has been confirmed with sera from two patients with fatal malaria, one patient with severe nonfatal malaria, and three patients with mild *P. falciparum* malaria.

Since neither ascorbic acid nor ulinastatin alone was able to suppress apoptotic endothelial cell damage completely, both substances were combined. At concentrations of $10^{-4} \text{M}$ ascorbic acid and $10^{-7} \text{M}$ ulinastatin, the apoptosis rate of 35% was lower than that with either substance alone at the respective concentration (ascorbic acid, 45%; ulinastatin, 43% [Fig. 2f]).

Since the effect of malaria patient serum on endothelial cells may depend upon the TNF-α present in the patient serum, a neutralizing anti-TNF-α antibody was tested with sera from two patients with fatal malaria. In the absence of neutrophils, the anti-TNF-α antibody reduced the endothelial apoptosis rate from 33 to 24% and from 33 to 26%, while in the presence of neutrophils, the antibody reduced the apoptosis rate from 50 to 30% and from 47 to 35% in the first and second sera, respectively.

Since the contents of neutrophil granules may cause endothelial apoptosis, the experiments were performed in the presence or absence of gabexate mesilate or pentoxifylline, both of which block secretion from neutrophil granulocytes (6, 36). However, addition of gabexate mesilate (0.1 to 100 µM) or pentoxifylline (1 to 100 µM) did not reduce the percentage of TUNEL-positive endothelial cell nuclei (Fig. 2a and b).

**Histopathology.** Observation of capillaries in kidney and lung tissues from two patients who had died from *P. falciparum* malaria showed TUNEL-positive endothelial cells with round and condensed nuclei, indicating that they were undergoing apoptosis (Fig. 1C, panels a and b). Much of the capillary endothelial cell layer was missing, suggesting malaria-induced...
endothelial damage or cell detachment, as previously suggested from in vitro experiments (23).

**DISCUSSION**

This study indicates that sera from patients with malaria induces endothelial apoptosis, which is amplified by neutrophils, and that endothelial apoptosis can be prevented by the neutralization of reactive oxygen species or proteolytic enzymes in vitro.

Neutrophils can be activated by TNF-α (23, 43, 44) and by *P. falciparum*-specific products (32), both present in significant amounts in the sera of patients with *P. falciparum* malaria before therapy (3, 10, 18, 30, 34, 37). Sera obtained 7 days after the initiation of therapy, when TNF-α levels and parasitemia had decreased, induced less endothelial apoptosis than sera obtained before therapy. Earlier, we had shown that anti-TNF-α antibodies protect endothelial cells from damage induced by patient serum (severe malaria) and neutrophils (23). In the present study, we show that anti-TNF-α antibodies reduce the apoptosis-inducing capacity of patient serum both in the presence and in the absence of neutrophils. TNF-α not only activates neutrophils and endothelial cells but also triggers endothelial cell apoptosis in a concentration- and time-dependent manner (41). This may explain why malaria patient serum can induce endothelial cell apoptosis independently of neutrophils, albeit at a lower level. However, the proapoptotic effect of patient serum correlates better with parasitemia than with TNF-α concentrations in serum. Therefore, parasite-derived products may also play a role in neutrophil-mediated endothelial apoptosis.

Reactive oxygen species and elastase, which are secreted by neutrophils, induce apoptosis of endothelial cells at low concentrations and necrosis at high concentrations (4, 7, 48, 57). In our experiments, staining with annexin V and propidium iodide confirmed that most of the endothelial damage was due to apoptosis. Likewise, we found apoptotic, rather than necrotic, endothelial cells in the renal and pulmonary blood vessels of patients with *P. falciparum* malaria who had died of multiorgan failure (Fig. 1C, panels a and b).

To prevent multiorgan failure in malaria, several intervention strategies have been studied in simian and murine models, including the administration of heparin (12), anti-TNF-α antibodies (17), pentoxifylline (33), or dexamethasone (14). However, in all these studies, the intervention had to be applied before the onset of disease to prevent organ failure and death. This is also true for neutrophil depletions, which protect mice from cerebral complications of *P. berghei* malaria only if performed before symptoms appear (8). Later, when death from cerebral malaria is imminent, only administration of an antibody against leukocyte function antigen 1, which blocks binding of neutrophil granuloctyes to the vascular endothelium via intercellular adhesion molecule 1, offers protection in this animal model (19). This is in agreement with our observation that direct contact between neutrophils and the vascular endothelium is essential for neutrophil-mediated endothelial apoptosis in the presence of malaria patient serum.

In human *P. falciparum* malaria, heparin (21), anti-TNF-α antibodies (52), and pentoxifylline (24, 35) have failed to provide any therapeutic benefit, while dexamethasone (which is known to induce endothelial apoptosis in vivo [15, 53]) was even deleterious (25, 54). Activated or apoptotic endothelial cells become procoagulant, reflected by decreased protein C and elevated plasma thrombin-antithrombin III levels in *P. falciparum* malaria (5, 22, 44). Heparin is beneficial in simian malaria (*P. knowlesi*) but not in human malaria (*P. falciparum*), where it fails to reverse these procoagulant alterations (12, 21).

Thus, one explanation for the failure of these intervention strategies is that they may come too late to inhibit the harmful pathophysiological events. Another reason may be that these intervention strategies cannot prevent endothelial damage and increased capillary permeability, which is a key to organ impairment in severe malaria (23, 27, 38). In contrast, an antiapoptotic strategy should prevent damage even when applied after activation of the host response.

Our study demonstrates that apoptosis of endothelial cells was reduced by the antioxidants ascorbic acid and tocopherol and by the protease inhibitor ulinastatin. In combination, ascorbic acid and ulinastatin were more effective than either substance alone but did not block endothelial apoptosis completely (Fig. 2f). The incremental effect of this combination over each individual substance is not proven to have biological significance. However, induction of endothelial damage by the joint action of reactive oxygen species and elastase has been demonstrated in an isolated rat lung model (2). This may be due to the fact that reactive oxygen species inactivate protease inhibitors which otherwise might protect the endothelium from the elastase-induced damage (46).

As shown in Fig. 2d, endothelial cell apoptosis was also significantly inhibited by tocopherol. The antioxidant tocopherol prevents apoptosis by inhibiting caspases (51). In murine *P. berghei* malaria, administration of the antioxidants butylhydroxyanisol or tocopherol prevents death from cerebral complications (49), suggesting that inhibition of apoptosis by this antioxidant may indeed be operative in vivo. However, while ascorbic acid and ulinastatin protected endothelial cells at concentrations that are achieved in humans, tocopherol was effective only at much higher concentrations.

None of the substances tested provided complete protection from apoptosis. This may be explained by the fact that substances directed against neutrophil-derived reactive oxygen species and proteases would not necessarily block neutrophil-independent apoptosis by TNF-α or other serum ingredients.

Nevertheless, the clinical benefit of an antiapoptotic strategy for endothelial protection has been illustrated in cardiovascular diseases. Just like the serum malaria samples in this study, serum samples from patients with cardiopulmonary bypass (1) or congestive heart failure (42) cause endothelial apoptosis in vitro. In agreement with this study, ascorbic acid prevents endothelial apoptosis in congestive heart failure in vitro and in vivo (42). The multivalent enzyme inhibitor ulinastatin neutralizes human neutrophil elastase in vitro (29) and improves pulmonary function (lower alveolar arterial oxygen gradient, or AaDO₂) in vivo (47).

The antiapoptotic strategy derived from our in vitro model may be relevant for *P. falciparum* malaria, since this disease is associated with both elevated levels of human neutrophil elastase in plasma (23, 26, 40) and a decreased serum antioxidative status with abnormally low levels of ascorbic acid (9). Thus, antioxidants and protease inhibitors may offer clinical benefit
by preventing organ complications due to endothelial apoptosis even though they may not accelerate parasite clearance or deferescence.

ACKNOWLEDGMENTS

The help of Volker Briesie (Department of Gynecology and Obstetrics, Rostock University Medical School) and Eckhard Koeppcke (Department of Gynecology and Obstetrics, Rostock City Hospital “Suedstadtiklinikum”) in providing umbilical cords is greatly appreciated. We thank Rudolf Wegener (Department of Forensic Medicine, Rostock University Medical School) and Horst Nizze (Department of Pathology, Rostock University Medical School) for technical assistance. We also thank Joachim Ryckyl (Department of Experimental Medicine, Rostock University Medical School) for permitting us to use the in-vitro fluorescence microscope and other facilities in his department.

Financial support was received from the German Research Foundation (Deutsche Forschungsgemeinschaft grant He 3137/2-1), the B. Braun Foundation, Melsungen, Germany (grant Hemmer 2004), and the Research Support Program, University of Rostock Medical School (grants FORUN 2002 and 2004).

REFERENCES

23. Laosaresuswan, S., P. Wilairatana, S. Vannapha, V. Wanaratana, C. We-
31. Prukittikayamee, S., R. Clemens, C. Prasunokinsap, H. E. Karges, S. Van-

Downloaded from http://iai.asm.org on January 20, 2020 by guest


